| Digg It |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Finance > As the Financial Industry Becomes More Complex, Universities Respond with Targeted Degrees |
|
Digg It - As the Financial Industry Becomes More Complex, Universities Respond with Targeted Degrees
With the rising power and importance of multinational corporations, the spread of globalization, a According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product nd the increased interest among a large segment of the population for investment opportunities (mu ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in h of it aimed toward retirement security), financial expertise is becoming more important in the w lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. orkplace, particularly for mid- and upper-level management. The vaunted MBAs of two decades ago p here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ovide information that is often too general to meet the needs of today’s internationally oriented d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro finance industry, and so colleges and universities have responded with more targeted degree progra ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc s. The programs cover financial theory and analysis, as well as team building and management skill easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi s, and are designed for practical application in the banking, investment, and insurance industries nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically The world of corporate financial decision making, which is geared toward maximizing company value and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ and shareholder returns, is finding value in the new degree programs, as are governmental agencie ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi at the local, state, and federal levels. These agencies, charged with making financial decisions ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a and crafting policy, look for new hires who have a solid understanding of finance. The best of th dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod graduate finance programs utilize the expertise of financiers with practical experience in the fi cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin eld. No ivory-tower academics here; the faculty includes industry leaders who often also participa tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen e in curriculum development. The finance industry is the fastest growing sector in the U.S. today t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel , which means that that’s where the jobs are, and will be, for some time to come. College graduate ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust entering the workforce with solid knowledge of finance will find themselves at an advantage over y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products colleagues with no financial background. Both collage graduates and those already in the workforce . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de should take a serious look at one of these gra elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip duate finance degrees; one of these targeted degrees may put them on the fast track to success tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Effective Time Management and Your Small Business Unsubscribe To Keep Your Sanity
|